Drugs / Ferroglycine Sulfate
Ferroglycine Sulfate
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02469480 Comparator | Mar 2015 → May 2020 | colorectal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03833336 Comparator | Aug 2017 → Sep 2024 | diastolic heart failure, iron deficiency anemia | Institut de Recerca Biomèdica de Lleida | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ferroglycine Sulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03833336 ↗ |
| Known as | Ferro sanol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02469480 ↗ |
| Known as | Ferrocontin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297671 ↗ |
| Known as | Ferroglycine sulfate complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297671 ↗ |
| Modality | Small molecule | — CHEMBL4297671 ↗ |
| Route | Oral | “Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution” NCT02469480 ↗ |